Gene or Genome – Page 7

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

3 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

3 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

3 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

3 months ago talkbio0Tagged BCG Vaccine, Blocker, Carcinoma of urinary bladder, invasive, Keytruda, Malignant neoplasm of urinary bladder, Non-Muscle, PDCD1 gene, Pfizer, Phase 3 trial, Sasanlimab

Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda

Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig

4 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, immuno-oncology, Inhibitor, Myers, PDCD1 gene, squibb, subcutaneous administration, United States Food and Drug Administration

Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.

Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis

4 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, Phase 3 Clinical Trials, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor

Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines

4 months ago talkbio0Tagged Adult, Bioscience, DKK1 gene, next-generation, PCV21, PCVs, Pediatric brand name, Phase III Testing, pneumococcal conjugate, sanofi, Vaccines

Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

4 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

4 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Jazz Pharmaceuticals Announces CEO Succession Plan as Co-Founder Bruce Cozadd Prepares to Retire

4 months ago talkbio0Tagged biopharmaceutical company, BIRC6 gene, CEO, Cozadd, Jazz, Leadership, Retirement, Succession Plan

Jazz Pharmaceuticals, Bruce Cozadd, CEO succession plan, retirement, biopharmaceutical company, leadership transition